Abstract
Human epidermal growth factor receptor-2 (HER-2) mediates a number of important cellular activities, and is up-regulated in a diverse set of cancer cell lines, especially breast cancer. Accordingly, HER-2 has been regarded as a common drug target in cancer therapy. Antibodies can serve as ideal candidates for targeted tumor imaging and drug delivery, due to their inherent affinity and specificity. Advanced by the development of a wide variety of imaging techniques, antibody-based imaging of HER-2 can allow for early detection and localization of tumors, as well as monitoring of drug delivery and tissue’s response to drug treatment. In this review article, antibody-based imaging of HER-2 are summarized and discussed, with an emphasis on the involved imaging methods.
Keywords: Antibody, drug delivery, magnetic resonance imaging (MRI), near-infrared fluorescence (NIRF) imaging, photoacoustic tomography (PAT), positron emission tomography (PET), radioimmunoscintigraphy (RIS), singlephoton emission computed tomography (SPECT).
Current Molecular Medicine
Title:Antibody-Based Imaging of HER-2: Moving into the Clinic
Volume: 13 Issue: 10
Author(s): R. E. Wang, Y. Zhang, L. Tian, W. Cai and J. Cai
Affiliation:
Keywords: Antibody, drug delivery, magnetic resonance imaging (MRI), near-infrared fluorescence (NIRF) imaging, photoacoustic tomography (PAT), positron emission tomography (PET), radioimmunoscintigraphy (RIS), singlephoton emission computed tomography (SPECT).
Abstract: Human epidermal growth factor receptor-2 (HER-2) mediates a number of important cellular activities, and is up-regulated in a diverse set of cancer cell lines, especially breast cancer. Accordingly, HER-2 has been regarded as a common drug target in cancer therapy. Antibodies can serve as ideal candidates for targeted tumor imaging and drug delivery, due to their inherent affinity and specificity. Advanced by the development of a wide variety of imaging techniques, antibody-based imaging of HER-2 can allow for early detection and localization of tumors, as well as monitoring of drug delivery and tissue’s response to drug treatment. In this review article, antibody-based imaging of HER-2 are summarized and discussed, with an emphasis on the involved imaging methods.
Export Options
About this article
Cite this article as:
Wang E. R., Zhang Y., Tian L., Cai W. and Cai J., Antibody-Based Imaging of HER-2: Moving into the Clinic, Current Molecular Medicine 2013; 13 (10) . https://dx.doi.org/10.2174/1566524013666131111120951
DOI https://dx.doi.org/10.2174/1566524013666131111120951 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Redox Status in Periodontal and Systemic Inflammatory Conditions Including Associated Neoplasias: Antioxidants as Adjunctive Therapy?
Infectious Disorders - Drug Targets PSMA7, A Potential Biomarker of Diseases
Protein & Peptide Letters Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery Camptothecins and Lung Cancer: Improved Delivery Systems by Aerosol
Current Cancer Drug Targets Pattern of Care for Skin Cancers - Canada and France
Current Cancer Therapy Reviews Synthesis, Molecular Targets, and Antitumor Activities of Substituted Tetrahydro-1- Oxopyrano[4,3-b][1]Benzopyrans and Nanogels for Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Endocrine, Metabolic & Immune Disorders - Drug Targets Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists
Current Topics in Medicinal Chemistry Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology Thermosensitive Polymeric Hydrogels As Drug Delivery Systems
Current Medicinal Chemistry Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry Targeted Cancer Therapy; Nanotechnology Approaches for Overcoming Drug Resistance
Current Medicinal Chemistry Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Inhibiting the “Undruggable” RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products
Current Medicinal Chemistry Bringing Light into the Diagnosis of Skin Disorders - Short Review on Laser Induced Fluorescence Spectroscopy and Optical Coherence Tomography in Dermatology
Current Medical Imaging OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Pharmacogenomics of Cytochrome P450 Enzymes in Tumours
Current Pharmacogenomics The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery